Oliver A. Cornely

TL;DR: In this paper, the authors report the incidence of Clostridioides difficile infection and assess potential clinical characteristics and biomarkers to predict CDI in 1,007 patients ≥ 50 years receiving newly initiated antibiotic treatment with penicillins plus a beta-lactamase inhibitor, 3rd/4th generation cephalosporins, carbapenems, fluoroquinolones or clindamycin from 34 European hospitals.

TL;DR: In FQ-treated hospitalized patients, DAV132 was well tolerated, and FQ plasma concentrations unaffected, and DAV132 preserved intestinal microbiota diversity and C. difficile colonization resistance.

TL;DR: LCA appears to be a promising marker candidate for prediction of clinical response to FMT, and other makers, such as urinary concentration of pCS, but not 3-IS, might be used to improve accuracy of prediction.

TL;DR: The final PBPK model of CAS without individualized parameter is able to predict the pharmacokinetics in different patient populations correctly and provides a basis for investigators to choose doses and sampling times for special populations such as infants and small children.